Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | PYGL | P06737 | 2/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7270673 | 0.84 | MTNR1A (0.53) | MTNR1AMTNR1BSMN1; SMN2NPSR1GRM7 | |
| SCHEMBL11138133 | 0.84 | MTNR1A (0.53) | MTNR1AMTNR1BSMN1; SMN2NPSR1GRM7 | |
| SCHEMBL6198595 | 0.84 | CNR1 (0.48) | CNR1PYGLMTNR1AMTNR1BMAPK1 | |
| SCHEMBL7273542 | 0.84 | MTNR1A (0.53) | MTNR1AMTNR1BSMN1; SMN2NPSR1GRM7 | |
| SCHEMBL2736650 | 0.83 | MTNR1A (0.47) | MTNR1AMTNR1BSMN1; SMN2NPSR1MAPK1 | |
| SCHEMBL2736653 | 0.83 | MTNR1A (0.47) | MTNR1AMTNR1BSMN1; SMN2NPSR1MAPK1 | |
| SCHEMBL8406936 | 0.83 | MTNR1A (0.59) | CNR1MTNR1AMTNR1B | |
| SCHEMBL26763722 | 0.83 | CNR1 (0.47) | CNR1PYGLMTNR1AMTNR1BMAPK1 | |
| SCHEMBL19797799 | 0.82 | MTNR1A (0.46) | MTNR1AMTNR1BSMN1; SMN2NPSR1MAPK1 | |
| SCHEMBL2467842 | 0.82 | MTNR1A (0.46) | MTNR1AMTNR1BSMN1; SMN2NPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | CNR1 1017/4885PYGL 2456/4885MTNR1A 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.